Incyte

ABOUT

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients and make a difference in healthcare. Incyte’s unique expertise in medicinal chemistry and biology has enabled us to establish a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity, including 24 clinical compounds in development.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. We have more than 2,500 employees, including more than 1,000 world-class scientists, who are committed to discovering first-in-class medicines for patients who previously had limited treatment options.

For more information about Incyte, please visit us at www.Incyte.com. Follow Incyte on X, LinkedIn, Facebook and Instagram.

1801 Augustine Cut-off, Wilmington, DE 19803

Visit website

NEWS

Drug Development

Relay Therapeutics’ Liver Cancer Approach Paying Early Dividends

Of these six patients, three had a partial response (PR) with their tumors shrinking by more than 30%.

October 8, 2021

2 min read

Heather McKenzie

Bio NC

Clinical Catch-Up: October 4-8

Another busy week for clinical trial news. Here’s a look.

October 8, 2021

16 min read

Mark Terry

FDA

New Atopic Dermatitis Option Available as FDA Approves Incyte’s Opzelura

FDA approved Incyte’s Opzelura (ruxolitinib) cream for atopic dermatitis (AD) for the short-term and non-continuous chronic treatment of mild to moderate AD.

September 22, 2021

3 min read

Mark Terry

Policy

FDA Action Alert: Incyte, Verrica and Ascendis

From time to time, the U.S. FDA requests additional data from companies who have submitted an application for a new drug or biologic. What’s a bit unusual is every single PDUFA date this week had that happen.

September 17, 2021

4 min read

Mark Terry

Drug Development

Clinical Catch-Up: August 2-6

It was a busy week for clinical trial announcements. Take a look.

August 6, 2021

7 min read

Mark Terry

Business

Eli Lilly in the News: COVID-19, Q2 and Ad Drama

Eli Lilly and Company is in the news with positive Olumiant data in COVID-19, a drop in COVID-19 product sales for the quarter and a protest of one of their ads. Here’s a look.

August 3, 2021

3 min read

Mark Terry

Drug Development

FDA Rejects Incyte’s PD-1 For Anal Cancer, Requires More Proof of Benefit

The FDA’s ODAC met to discuss retifanlimab and voted 13-4 that a regulatory decision for the drug for this indication should be deferred until more data was available.

July 26, 2021

2 min read

Mark Terry

Drug Development

FDA Action Alert: Incyte, Iterum and Ardelyx

The U.S. Food and Drug Administration (FDA) had several PDUFA dates on their calendar for the last week of July, but in two cases, there were problems with the submissions ahead of time. Here’s a look.

July 23, 2021

3 min read

Mark Terry

Drug Development

ODAC Votes to Defer Decision on Incyte’s PD-1 Inhibitor for Squamous Cell Carcinoma

The Oncologic Drugs Advisory Committee (ODAC), as part of the U.S. Food and Drug Administration (FDA), has voted 13-to-4 against supporting the accelerated approval of Incyte’s PD-1 inhibitor for squamous cell carcinoma.

June 25, 2021

3 min read

Brandon May

AWARDS